Independent and not affiliated with the FDA, MHRA, ISPE, PDA, or any agency. Get the appgoutham@madhadi.com
madhadi.comData Integrity & GxP Quality
Browse all topics → Articles Templates & Procedures Learning paths GlossaryScenariosToolsRegulatory ReferencesLearning PathsTopics About Start here
Topic area

Quality Assurance & QMS

The quality management system is the framework that keeps a regulated operation in a state of control. This pillar covers ICH Q10, CAPA, deviation and change management, document control, process and cleaning validation, OOS investigations, stability, supplier qualification, training, and quality metrics.

52 articles
Beginner

Certificate of Analysis and Certificate of Compliance: Reading, Issuing, and Verifying

How to read, issue, and verify a Certificate of Analysis and a Certificate of Compliance in a GMP environment, including spec linkage, transcription and data integrity risk, supplier reliance, and skip-lot testing.

Beginner

21 CFR 210 and 211 Walkthrough: The US cGMP Regulation Subpart by Subpart

A structured map of the US current Good Manufacturing Practice regulation for finished drugs, walking through every subpart of 21 CFR Part 211 with the contents, roles, and inspection findings a QA professional needs to cite it from memory.

Beginner

Deviation Management in GxP: Classification, Investigation, and Resolution

How GMP deviations move from first report through closure: classification criteria, investigation depth, impact assessment, batch disposition, trending, and what separates a real investigation from a paperwork exercise.

Beginner

Document Control in GxP: How Controlled Documents Actually Work

A working guide to GxP document control: the document hierarchy, SOP lifecycle, version control, effective dates, training linkage, electronic systems, and what inspectors cite.

Beginner

Interview Preparation for GxP Quality, CSV, and Validation Roles

A working question bank and answer frameworks for GxP quality, computer system validation, and validation interviews. Covers GAMP categories, the V-model, traceability, Part 11, and CAPA/deviation/OOS scenarios.

Beginner

GxP Roles Explained: Who Does What in a Regulated Biotech or Pharma Company

A practical map of every quality and compliance role in a regulated organization, what each function owns, how the roles interact, the regulatory basis for each separation, and the interview questions asked about them.

Beginner

How to Write an SOP People Actually Follow: Structure, Language, and Common Failures

A step-by-step guide to authoring GxP standard operating procedures that are accurate, usable, and inspection-ready, with templates, sample text, and the failure patterns regulators cite.

Beginner

The Quality Manual and QMS Document Hierarchy: Policies, SOPs, Work Instructions, and Records

How a GxP quality management system is structured as a document pyramid, from the quality manual down to executed records, with the contents, owners, and acceptance criteria for each tier.

Beginner

What Is a CAPA? Corrective and Preventive Action Explained

CAPA is the backbone of every quality management system. This guide explains what CAPA is, when it's triggered, how to run one end to end, and what separates an effective CAPA from a compliance checkbox.

Beginner

What Is GMP? A Plain-Language Introduction to Good Manufacturing Practice

GMP explained without the bureaucratic fog. What the regulations actually require, why they exist, the records they generate, and how to work inside the system well enough to pass an inspection or an interview.

Beginner

Why Validation Matters: Proving That Systems and Processes Actually Work

A plain-language explanation of what validation is, why it matters for patient safety and trustworthy data, and the regulations that actually require it, for anyone new to GxP.

Intermediate

Annual Product Review and the Product Quality Review (PQR)

How to run the yearly batch-record retrospective required by 21 CFR 211.180(e) and EU GMP Chapter 1, what data feeds it, how trends drive CAPA, and what inspectors actually read.

Intermediate

Batch Disposition: How Release, Reject, and Quarantine Decisions Get Made

How quality units decide to release, reject, or hold a manufactured batch: the regulatory basis, the review sequence, conditional and parametric release, and the QA versus QP roles that sign off.

Intermediate

Batch Record Review: What It Is, What to Look For, and What Regulators Expect

A practical guide to GMP batch record review: the process, what makes a batch record complete, how to conduct a meaningful review, common failures, and how automated systems change the picture.

Intermediate

CAPA Effectiveness Checks: Designing Verification That Proves the Fix Worked

How to design effectiveness verification for CAPAs that holds up in an inspection: real metrics, the right timing window, objective evidence, and closure criteria that prove the corrective action actually worked.

Intermediate

CDMO Oversight and Quality Agreements

How to allocate GMP responsibilities, retain audit rights, and control data integrity when manufacturing or testing is outsourced to a contract organization.

Intermediate

Cleaning Validation in Pharmaceutical Manufacturing: ADE, PDE, and the Full Framework

An operational guide to cleaning validation: the regulatory basis, ADE/PDE calculations, worst-case product selection, swab and rinse sampling design, acceptance criteria, and what inspectors focus on.

Intermediate

Clinical Systems and GCP Digital Quality: EDC, IRT, eTMF, and CTMS

A practical guide to computerized systems in clinical trials: EDC, IRT/RTSM, eTMF, CTMS, and safety databases. What validation means for clinical systems, what FDA and ICH E6 require, who owns what between sponsor and vendor, and what inspectors check in a BIMO inspection.

Intermediate

Combination Products: cGMP Compliance Under 21 CFR Part 4

How drug-led and biologic-led combination products (prefilled syringes, autoinjectors, on-body delivery systems) are manufactured to cGMP: primary mode of action, the streamlined Part 4 approach, which provisions you add to a drug or biologics base system, and how to survive an inspection.

Intermediate

Cross-Contamination Control in Shared Facilities: Dedicated Equipment, Campaigning, and HBELs

How to control cross-contamination in multi-product GMP facilities using health-based exposure limits, equipment dedication decisions, campaign production, and the EMA criteria for when a dedicated facility is required.

Intermediate

When Human Error Is Not a Root Cause: Investigating and Preventing Repeat Deviations

Why regulators reject human error as a root cause, and how to run deviation investigations that find the real systemic failure using human-factors analysis, poka-yoke, and CAPA that actually holds.

Intermediate

ICH Q7: GMP for Active Pharmaceutical Ingredients

How ICH Q7 sets the GMP rules for active pharmaceutical ingredients, where GMP begins for starting materials, API process validation, impurity control, supply-chain change control, the quality unit's role, and how Q7 underpins both small-molecule synthesis and biologic drug substance.

Intermediate

IND, NDA, and BLA: US Regulatory Pathways From First-in-Human to Approval

How a drug or biologic moves through the US system from IND to approval: what each submission contains, the clinical phases, the expedited programs, and the review clock that runs underneath it all.

Intermediate

Management Review: Running the Meeting That Proves the Quality System Works

How to run an ICH Q10 management review that actually demonstrates control: the required inputs, the cadence, escalation paths, action tracking, and how to present it to an inspector.

Intermediate

OOS Investigations: The Step-by-Step Process FDA Expects

An operational walkthrough of out-of-specification investigations: Phase 1 laboratory assessment, Phase 2 full investigation, assignable cause determination, retest and resample rules, batch disposition, roles, timelines, and exactly what inspectors examine.

Intermediate

Out-of-Trend (OOT) Results: Detection, Statistical Triggers, and Investigation

How to detect, flag, and investigate out-of-trend results in pharmaceutical quality, with a focus on stability data, statistical limits, and the investigation procedure. Built for QA, QC, and stability practitioners.

Intermediate

ICH Q10: The Pharmaceutical Quality System Framework

What ICH Q10 actually requires, how the four QMS elements connect to GMP compliance, and how data integrity, CSV, and quality risk management fit into a coherent quality system you can defend in an inspection.

Intermediate

Product Complaint Handling: Intake, Investigation, Trending, and Regulatory Reporting

How to run a product complaint system end to end for drugs, biologics, and cell and gene therapies: intake across every channel, triage, the adverse-event fork and its reporting clocks, sample custody, investigation, CAPA linkage, trending, supply-chain handoffs, and system health metrics.

Intermediate

QMS Self-Audit: Evaluating Your Pharmaceutical Quality Management System

A complete QMS self-audit framework covering document control, deviation and CAPA management, change control, training, supplier qualification, internal audits, and quality metrics. Structured around ICH Q10 and FDA/EMA expectations, with worked examples, roles, and interview questions.

Intermediate

Triaging Quality Events: Critical, Major, Minor Classification and Risk Ranking

How to classify GMP quality events as critical, major, or minor, set investigation depth and escalation thresholds, and rank risk against patient impact. Decision trees, worked examples, and the inspection findings that follow weak triage.

Intermediate

Quality Metrics and KPIs: Building a Dashboard Inspectors and Executives Both Trust

How to design, calculate, and govern a GxP quality metrics program that survives inspection and drives real decisions, with worked formulas for RFT, OOS rate, CAPA aging, and lot acceptance.

Intermediate

Quality Risk Management: ICH Q9(R1), FMEA, and Risk-Based Decision Making in GxP

How to apply ICH Q9(R1) quality risk management in practice: FMEA, risk ranking, risk assessment methodology, scoring scales, and when to use which tool. Written for people who have to apply it, not just cite it.

Intermediate

Root Cause Analysis in GxP: 5 Whys, Fishbone, Fault Tree, and How to Pick One

A working guide to root cause analysis for pharma and biotech quality. Covers 5 Whys, Ishikawa, fault tree, Is/Is-Not, contributing versus root cause, and how to write an RCA that survives an inspection.

Intermediate

Stability Programs in Pharmaceutical QA: ICH Q1A Through Q1F in Practice

An operational guide to pharmaceutical stability programs: ICH storage conditions, stability-indicating methods, shelf life determination, accelerated and long-term studies, ongoing stability, and what FDA and EMA reviewers look for in a stability data package.

Intermediate

Statistics in QA: Sampling, Process Capability, Control Charts, and OOT

A working guide to the four statistical tools every quality practitioner is expected to apply: attribute sampling plans, Cp/Cpk/Ppk capability, Shewhart control charts, and out-of-trend detection feeding continued process verification.

Intermediate

Supplier and Vendor Qualification in GxP: From Approved Vendor List to Audit

A practical guide to GxP supplier qualification: the approved vendor list, risk-based qualification levels, audit programs, ongoing monitoring, quality agreements, and how to qualify cloud and SaaS vendors under 21 CFR Part 11.

Intermediate

Technical Writing for GxP: Protocols, Reports, Deviations, and Defensible Documentation

How to write GxP records that survive inspection: objective tone, contemporaneous entries, and investigation narratives that hold up under scrutiny. Covers protocols, reports, deviations, and the documentation conventions inspectors check.

Intermediate

GxP Training Program Design: Building a System That Actually Changes Behavior

How to design and run a GxP training program that meets regulatory requirements, creates defensible training records, and teaches people to work compliantly. Covers the training matrix, methods, effectiveness checks, LMS validation, records, and what inspectors examine.

Advanced

Cleaning Validation Execution: Swab and Rinse Sampling, Recovery Studies, MACO, and TOC

How to actually run cleaning validation on the floor: sampling location selection, swab and rinse recovery studies, MACO calculation from health-based limits, worst-case grouping, hold times, and TOC versus specific analytical methods.

Advanced

Continued Process Verification: Building a Stage 3 CPV Program

How to design and run a Stage 3 Continued Process Verification program: trending plans, control charts, statistical signal rules, the CPV protocol, and the annual CPV report. Built for biologics and small molecule manufacturers under the FDA lifecycle model.

Advanced

The eCTD and Regulatory Submission Architecture: Modules 1 to 5 and Data Integrity in Filings

How the Common Technical Document and eCTD work in practice: the five modules, lifecycle sequences, publishing and validation, and the data integrity controls that keep a filing inspection-defensible.

Advanced

Extractables and Leachables: Assessing What Migrates Into a Product

A working account of extractables and leachables: why they matter, how to design controlled extraction and leachable studies, the USP chapters and ISO standards that govern them, safety thresholds like the SCT and AET, single-use systems, and the findings that recur in review and inspection.

Advanced

ICH Q12: Product Lifecycle Management and Established Conditions

An operational guide to managing post-approval CMC changes with regulatory predictability using ICH Q12 established conditions, PLCM documents, and post-approval change management protocols.

Advanced

Analytical Procedure Lifecycle: ICH Q14 and Q2(R2)

How ICH Q14 and the revised Q2(R2) reframe analytical methods as lifecycle-managed entities, from the analytical target profile through validation, transfer, and continued performance verification.

Advanced

Impurities and Nitrosamines: ICH Q3, M7, and Risk-Based Control

A guide to controlling organic, inorganic, and mutagenic impurities under ICH Q3 and M7, plus the nitrosamine risk-assessment workflow and the data-integrity demands of impurity testing.

Advanced

The PPQ Protocol: Designing and Executing Stage 2 Process Performance Qualification

How to design, run, and report Process Performance Qualification batches: the number-of-batches rationale, sampling plans, acceptance criteria, enhanced sampling, and the PPQ report that survives inspection.

Advanced

Process Validation for Biologics: Viral Clearance, Resin Lifetime, and Column Studies

How to run process validation for monoclonal antibodies and other biologics, covering viral clearance studies, chromatography resin and membrane lifetime, hold-time studies, and in-process pool acceptance criteria.

Advanced

Process Validation Lifecycle: Stage 1, 2, and 3 Under ICH Q8/Q9/Q10

A working guide to process validation using the three-stage lifecycle: process design, process qualification, and continued process verification, with practical detail on studies, documentation, statistics, roles, and regulatory expectations.

Advanced

Qualified Person Certification and EU Batch Release: Annex 16 in Practice

How the EU Qualified Person certifies and releases batches under Annex 16, including the QP declaration, reliance on others, multi-site supply chains, and what inspectors check.

Advanced

Quality by Design and Design of Experiments: CQAs, CPPs, and the Design Space

A working guide to ICH Q8 QbD and DoE for process design: how to define the QTPP, identify CQAs and CPPs through risk ranking, build and verify a design space, and turn it into a control strategy.

Advanced

Quality in Technology Transfer: Site-to-Site, R&D-to-GMP, and the Transfer Protocol

How quality teams run a controlled technology transfer: the transfer protocol, knowledge transfer, process and analytical method transfer, acceptance criteria, and the roles that keep it defensible.

Advanced

Recalls and Field Alerts: Classification, Execution, and Effectiveness

How drug and biologic recalls are classified, executed, and verified, covering Class I/II/III decisions, FDA notification timelines, mock recalls, reconciliation, effectiveness checks, and field alert reports.

Use madhadi.com as an app Full screen, works offline, one tap from your home screen.